Equities research analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to report sales of $4.32 million for the current quarter, according to Zacks. Four analysts have issued estimates for Aduro BioTech’s earnings, with estimates ranging from $3.70 million to $6.05 million. Aduro BioTech reported sales of $3.88 million during the same quarter last year, which would suggest a positive year over year growth rate of 11.3%. The company is expected to issue its next quarterly earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Aduro BioTech will report full-year sales of $4.32 million for the current year, with estimates ranging from $17.19 million to $19.50 million. For the next fiscal year, analysts expect that the firm will post sales of $33.03 million per share, with estimates ranging from $15.02 million to $74.82 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Aduro BioTech.
A number of research firms have recently issued reports on ADRO. BidaskClub downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Saturday. ValuEngine downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. HC Wainwright set a $10.00 price target on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Tuesday, January 16th. Canaccord Genuity set a $30.00 price target on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Thursday, December 14th. Finally, Oppenheimer reduced their price target on shares of Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Aduro BioTech presently has a consensus rating of “Buy” and an average price target of $17.71.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Aduro BioTech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after acquiring an additional 129,079 shares in the last quarter. Baillie Gifford & Co. grew its holdings in Aduro BioTech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after acquiring an additional 130,390 shares in the last quarter. Artal Group S.A. grew its holdings in Aduro BioTech by 100.0% during the 3rd quarter. Artal Group S.A. now owns 200,000 shares of the biotechnology company’s stock worth $2,130,000 after acquiring an additional 100,000 shares in the last quarter. State Street Corp grew its holdings in Aduro BioTech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after acquiring an additional 52,597 shares in the last quarter. Finally, Swiss National Bank grew its holdings in Aduro BioTech by 30.6% during the 2nd quarter. Swiss National Bank now owns 50,300 shares of the biotechnology company’s stock worth $573,000 after acquiring an additional 11,800 shares in the last quarter. Institutional investors own 45.14% of the company’s stock.
Shares of Aduro BioTech (NASDAQ:ADRO) opened at $6.25 on Wednesday. Aduro BioTech has a 52 week low of $5.85 and a 52 week high of $14.05.
TRADEMARK VIOLATION NOTICE: “$4.32 Million in Sales Expected for Aduro BioTech Inc (ADRO) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/07/4-32-million-in-sales-expected-for-aduro-biotech-inc-adro-this-quarter-2.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.